Cargando…

Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities

Glioma are the most common type of malignant brain tumor, with glioblastoma (GBM) representing the most common and most lethal type of glioma. Surgical resection followed by radiotherapy and chemotherapy using the alkylating agent Temozolomide (TMZ) remain the mainstay of treatment for glioma. While...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daniel, Paul, Sabri, Siham, Chaddad, Ahmad, Meehan, Brian, Jean-Claude, Bertrand, Rak, Janusz, Abdulkarim, Bassam S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369148/ https://www.ncbi.nlm.nih.gov/pubmed/30778375 http://dx.doi.org/10.3389/fonc.2019.00041

Ejemplares similares

Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma
por: Daniel, Paul, et al.
Publicado: (2022)

Radiomics in Glioblastoma: Current Status and Challenges Facing Clinical Implementation
por: Chaddad, Ahmad, et al.
Publicado: (2019)

Integration of Radiomic and Multi-omic Analyses Predicts Survival of Newly Diagnosed IDH1 Wild-Type Glioblastoma
por: Chaddad, Ahmad, et al.
Publicado: (2019)

Mechanisms and therapeutic implications of hypermutation in gliomas
por: Touat, Mehdi, et al.
Publicado: (2020)

The strategy for enhancing temozolomide against malignant glioma
por: Nakada, Mitsutoshi, et al.
Publicado: (2012)

SYST-08. A phase II trial of concurrent Sunitinib, Temozolomide and Radiation Therapy followed by adjuvant Temozolomide for newly diagnosed Glioblastoma patients with an unmethylated MGMT gene promoter (A01-M121-11A, McG1132)
por: Faye, Mame Daro, et al.
Publicado: (2021)

A Potential Mechanism of Temozolomide Resistance in Glioma–Ferroptosis
por: Hu, Zhifang, et al.
Publicado: (2020)

Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma
por: Noll, Alyssa, et al.
Publicado: (2023)

ITGA5 Predicts Dual-Drug Resistance to Temozolomide and Bevacizumab in Glioma
por: Shi, Ying, et al.
Publicado: (2021)

Identification and verification of the temozolomide resistance feature gene DACH1 in gliomas
por: Gu, Qiang, et al.
Publicado: (2023)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Predicting survival time of lung cancer patients using radiomic analysis
por: Chaddad, Ahmad, et al.
Publicado: (2017)

Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic
por: Bian, David J. H., et al.
Publicado: (2022)

CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing CDNK1A Transcription
por: Ye, Xiang, et al.
Publicado: (2021)

miR-9-5p Mediates ABCC1 to Elevate the Sensitivity of Glioma Cells to Temozolomide
por: Chen, Xiang-Rui, et al.
Publicado: (2021)

Ferroptosis in Glioma Immune Microenvironment: Opportunity and Challenge
por: Wang, Kaikai, et al.
Publicado: (2022)

Opportunities and challenges related to ferroptosis in glioma and neuroblastoma
por: Chi, Huizhong, et al.
Publicado: (2023)

Comprehensive Genomic Profiling of 282 Pediatric Low‐ and High‐Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures
por: Johnson, Adrienne, et al.
Publicado: (2017)

Mutator/Hypermutable Fetal/Juvenile Metakaryotic Stem Cells and Human Colorectal Carcinogenesis
por: Kini, Lohith G., et al.
Publicado: (2013)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas
por: Abe, Hideaki, et al.
Publicado: (2020)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53–PUMA Apoptosis Pathway
por: Tsai, Hong-Chieh, et al.
Publicado: (2021)

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
por: Yoshimoto, Koji, et al.
Publicado: (2012)

Evolutionary Dynamics of Asexual Hypermutators Adapting to a Novel Environment
por: Ho, Wei-Chin, et al.
Publicado: (2021)

Temozolomide – Just a Radiosensitizer?
por: Kaina, Bernd, et al.
Publicado: (2022)

Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
por: Aslan, Katrin, et al.
Publicado: (2020)

Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities
por: Gojo, Johannes, et al.
Publicado: (2020)

Study of Combinatorial Drug Synergy of Novel Acridone Derivatives With Temozolomide Using in-silico and in-vitro Methods in the Treatment of Drug-Resistant Glioma
por: Chakravarty, Malobika, et al.
Publicado: (2021)

METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m(6)A Dependent Manner
por: Shi, Jia, et al.
Publicado: (2021)

Mechanical Properties in the Glioma Microenvironment: Emerging Insights and Theranostic Opportunities
por: Bhargav, Adip G., et al.
Publicado: (2022)

Hypermutation as an Evolutionary Mechanism for Achromobacter xylosoxidans in Cystic Fibrosis Lung Infection
por: Veschetti, Laura, et al.
Publicado: (2020)

Radiomics Evaluation of Histological Heterogeneity Using Multiscale Textures Derived From 3D Wavelet Transformation of Multispectral Images
por: Chaddad, Ahmad, et al.
Publicado: (2018)

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
por: Teraiya, Milan, et al.
Publicado: (2023)

Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas
por: Ulasov, Ilya, et al.
Publicado: (2013)

Evidence of somatic hypermutation in the antigen binding sites of patients with CLL harboring IGHV genes with 100% germline identity
por: Sofou, Electra, et al.
Publicado: (2022)

Organized Pneumonia Secondary to Increasing Doses of Temozolomide
por: Marcos, Pedro J, et al.
Publicado: (2015)

Contribution of DNA polymerase η to immunoglobulin gene hypermutation in the mouse
por: Delbos, Frédéric, et al.
Publicado: (2005)

O(6)-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy
por: Yu, Wei, et al.
Publicado: (2020)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
por: Martin, Sophie, et al.
Publicado: (2012)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t96pda8jt5120bqdq146kjuah6